ALZHEIMER’S & DEMENTIA / EVIDENCE TO EXPERIMENT
Separate the diseases.
Separate pathology from function.
This research program tracks what is known, what failed, what remains uncertain, and which experiments could most reduce uncertainty about prevention, disease modification, resilience, and functional recovery.
Independent, AI-assisted evidence synthesis for scientific review. Not independently peer reviewed.
Do not collapse every dementia into Alzheimer’s
Alzheimer’s disease is kept distinct from Lewy body, frontotemporal, vascular, LATE, and mixed-pathology dementias.
02 / FUNCTIONBiomarkers are not the endpoint
Pathology and biomarker movement are tracked separately from cognition, daily function, durability, and quality of life.
03 / DECISIVE TESTSAsk what would change the conclusion
Negative evidence, competing explanations, falsifiers, and the smallest high-information experiment remain first-class parts of the record.
What the program keeps separate
Research is organized by disease and stage rather than treating dementia as one biological condition. Mixed pathology is common enough that a single diagnostic label may not explain every symptom or treatment response. Public summaries therefore preserve subtype, stage, population, and outcome context.
What counts as meaningful progress
Earlier detection and better biomarkers can improve diagnosis and research, but they are not interchangeable with preventing decline, restoring function, or producing durable clinical benefit. The program distinguishes risk prediction, pathology change, cognitive outcomes, functional outcomes, adverse effects, and durability.
Prevention, interception, and resilience
The research agenda includes risk reduction, preclinical interception, vascular and metabolic contributors, immune and glial biology, proteostasis, mitochondrial quality, synaptic and network function, and why some people remain functionally resilient despite pathology. Each line is treated as a question to test rather than a treatment recommendation.
Failed and negative evidence matters
Trials or mechanisms that do not produce the expected benefit are preserved because they narrow the search space. A useful research record should state the strongest evidence for an idea, the strongest evidence against it, major confounders, safety or feasibility limits, and what result would justify narrowing or abandoning the idea.
Public-safe sources
For general background on Alzheimer’s disease and related dementias, diagnosis, biomarkers, and ongoing research, see the U.S. National Institute on Aging.
NIA: How biomarkers help diagnose dementia
NIA: Alzheimer’s and related dementias research progress